ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - Magnetic resonance imaging/ultrasound-fusion biopsy better predicts whole gland pathology on radical prostatectomy compared to standard 12-core biopsy - Session Highlights

ORLANDO, FL USA (UroToday.com) - In men suspected of having prostate cancer, the current standard is ultrasound-guided template 12-core biopsy to determine the grade and relative burden of disease. However, this procedure has its pitfalls: up to one-third of men have higher grade disease found at radical prostatectomy. Multiple studies over the past several years have demonstrated that MRI-ultrasound fusion-guided biopsy, which layers previously obtained MRI data over a real-time ultrasound image, allows for targeting of lesions in the prostate and is more accurate than 12-core biopsy. While an eventual aim might be for targeted biopsy to supplement or even replace template biopsy, the major limitation of these studies is a lack of comparison of the targeted biopsy results to final pathology. The accuracy of preoperative histology is an essential component of treatment planning – specifically in patients who are candidates for active surveillance. In a six-year analysis of men who underwent radical prostatectomy at the National Cancer Institute, Dr. Arvin George and colleagues sought to evaluate the performance of targeted biopsy and standard 12-core biopsy as compared to the definitive pathology obtained after surgery.

auaThe authors prospectively collected data on patients who underwent MR-ultrasound fusion and standard 12-core biopsies in the same session, and who subsequently went on to have radical prostatectomy. Cancers detected by either biopsy method and on final surgical pathology were compared in terms of the overall Gleason sum. Nearly one-half of template 12-core biopsies undergraded cancer compared to 32% of MRI-ultrasound fusion biopsies. This difference was more pronounced when accounting for high-grade disease, with 53% of 12-core biopsies being upgraded to Gleason ≥ 8, almost double the rate of targeted biopsy. These findings demonstrate that MRI-ultrasound fusion biopsy is more representative of the Gleason grade. Though upgrading still occurred from targeted biopsy to final pathology, this study may herald further acceptance of targeted prostate biopsy as a potential adjunct or successor to standard 12-core biopsy.

Presented by Arvin George at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

National Cancer Institute (NCI), Bethesda, MD USA

Written by Nabeel A. Shakir and Zhamshid Okhunov, University of California (Irvine), and medical writers for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe